![James Smith](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Nick Glover | M | 55 |
YM BioSciences, Inc.
![]() YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 10 jaar |
Mary Christina Thomson | F | 53 | 2 jaar | |
Nicole Onetto | M | 71 |
YM BioSciences, Inc.
![]() YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 5 jaar |
Robert E. Pelzer | M | 70 | 7 jaar | |
Justin T. Huang | M | - | - | |
Stephen Dilly | M | 64 | 2 jaar | |
Andrew Sinclair | M | 52 | 3 jaar | |
Georgia Erbez | F | 57 | 1 jaar | |
Christy Oliger | F | 54 | 1 jaar | |
Barbara Klencke | M | 66 | 7 jaar | |
Philip Frost | M | 84 |
YM BioSciences, Inc.
![]() YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 5 jaar |
Tryon Williams | M | 84 |
YM BioSciences, Inc.
![]() YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 17 jaar |
Daniel J. Estes | M | 43 | 2 jaar | |
Gregg Smith | M | - |
YM BioSciences, Inc.
![]() YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 7 jaar |
Alvin Vitangcol | M | 49 | 3 jaar | |
Kapil Dhingra | M | 64 |
YM BioSciences, Inc.
![]() YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 1 jaar |
Jeffrey Cooper | M | 68 | 6 jaar | |
Andrew Allen | M | 57 | 5 jaar | |
Wendi V. Rodrigueza | M | 58 | 10 jaar | |
Emma McCann | F | - | 8 jaar | |
Tran Nguyen | M | 50 | 3 jaar | |
Donald Parfet | M | 71 | 4 jaar | |
Albert Cha | M | 51 | 2 jaar | |
James Topper | M | 62 | 3 jaar | |
Peter Thompson | M | 64 | 1 jaar | |
Craig Collard | M | 58 | 2 jaar | |
François Thomas | M | 66 |
YM BioSciences, Inc.
![]() YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 5 jaar |
Gaurav Aggarwal | M | 51 | 3 jaar | |
Mona Ashiya | M | 55 | 3 jaar | |
Catherine Mackey | M | 68 |
YM BioSciences, Inc.
![]() YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 2 jaar |
Kevin Thomas Ryan | M | - | - | |
Diane Gardiner | F | - | - | |
Josh Richardson | M | 42 | 3 jaar | |
Christian Hassig | M | 52 | - | |
Amy Barrier Altshul | F | - | - | |
Kevin Norrett | M | 51 | 2 jaar | |
Simon Eastman | M | - | - | |
Lauren Rose Musto | F | - | 1 jaar | |
Keith E. Anderson | M | 55 | 7 jaar | |
Sukhi Jagpal | M | 50 | 7 jaar | |
Wendy Chapman | F | 58 | 8 jaar | |
Denis G. Bosc | M | - |
YM BioSciences, Inc.
![]() YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 2 jaar |
Chandra D. Lovejoy | F | 52 | 3 jaar | |
Mark Kowalski | M | 69 | 5 jaar | |
William D. Turner | M | 58 | 2 jaar | |
Angie You | M | 51 | 4 jaar | |
Richard A. Messmann | M | 67 | 4 jaar | |
Alexandra Marie Nieves Gonzalez | F | - | - |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 42 | 87.50% |
Verenigd Koninkrijk | 9 | 18.75% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- James Smith
- Persoonlijk netwerk